Payment overview · 2025
General Payments
$52.35
3 reported records · 3 companies
Healthcare provider profile · identity verified
David J Ensz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH SIOUX CITY, NE · NPI 1124245899
Verified facts
What the public records show
CMS Open Payments records show David J Ensz, M.D. received $52.35 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.33 | 38.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.46 | 33.4% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $14.56 | 27.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.35 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 103 |
| Losartan Potassium | Losartan Potassium | 376 | 104 |
| Metformin Hcl | Metformin Hcl | 332 | 99 |
| Lisinopril | Lisinopril | 302 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 82 |
| Warfarin Sodium | Warfarin Sodium | 265 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 61 |
| Omeprazole | Omeprazole | 256 | 60 |
| Eliquis | Apixaban | 249 | 47 |
| Simvastatin | Simvastatin | 247 | 71 |
| Furosemide | Furosemide | 246 | 68 |
| Gabapentin | Gabapentin | 237 | 60 |
| Potassium Chloride | Potassium Chloride | 204 | 47 |
| Celecoxib | Celecoxib | 202 | 74 |
| Allopurinol | Allopurinol | 187 | 44 |
| Carvedilol | Carvedilol | 169 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 41 |
| Sertraline Hcl | Sertraline Hcl | 165 | 37 |
| Tramadol Hcl | Tramadol Hcl | 156 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 126 | 19 |
| Trazodone Hcl | Trazodone Hcl | 125 | 30 |
| Finasteride | Finasteride | 119 | 29 |
| Donepezil Hcl | Donepezil Hcl | 111 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 34 |
| Ozempic | Semaglutide | 103 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Ezetimibe | Ezetimibe | 96 | 23 |
| Lorazepam | Lorazepam | 96 | 30 |
| Farxiga | Dapagliflozin Propanediol | 95 | 23 |
| Mirtazapine | Mirtazapine | 93 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 21 |
| Metformin Hcl Er | Metformin Hcl | 89 | 17 |
| Alendronate Sodium | Alendronate Sodium | 88 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 25 |
| Glipizide | Glipizide | 85 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 21 |
| Alprazolam | Alprazolam | 77 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 13 |
| Entresto | Sacubitril/Valsartan | 70 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 29 |
| Memantine Hcl | Memantine Hcl | 67 | 13 |
| Bumetanide | Bumetanide | 66 | 17 |
| Meloxicam | Meloxicam | 65 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 64 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 14 |
| Myrbetriq | Mirabegron | 64 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | 15 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 59 | 14 |
| Fluconazole | Fluconazole | 57 | 23 |
| Pregabalin | Pregabalin | 56 | 17 |
| Spironolactone | Spironolactone | 56 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 31 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Cefdinir | Cefdinir | 53 | 43 |
| Nystatin | Nystatin | 52 | 28 |
| Valsartan | Valsartan | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 37 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Methylprednisolone | Methylprednisolone | 46 | 41 |
| Ondansetron Odt | Ondansetron | 46 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 34 |
| Famotidine | Famotidine | 45 | 13 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | 13 |
| Amoxicillin | Amoxicillin | 42 | 34 |
| Prednisone | Prednisone | 42 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Topiramate | Topiramate | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Glipizide Er | Glipizide | 37 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 29 |
| Calcitriol | Calcitriol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 18 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Mesalamine Er | Mesalamine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Victoza 3-Pak | Liraglutide | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.35 · 3 records | AstraZeneca Pharmaceuticals LP | FARXIGA, QULIPTA, UBRELVY, WAYRILZ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error